Viewing allergens as protoxins may therefore allow outlining a
path for the development of more
efficient immunotherapies .
4. Ishizaka, K. & Ishizaka, T.
Identification of γE-Antibodies as a Carrier of Reaginic Activity1.The Journal of Immunology 99 , 1187-1198 (1967).
5. Johansson, S.G., Bennich, H. &
Wide, L. A new class of immunoglobulin in human serum. Immunology14 , 265-272 (1968).
6. Till, S. Immunotherapy:
readdressing the balance between TH2 and TH1 cells. Vol. 27 981-985
(Wiley Online Library, 1997).
7. Celebi Sözener, Z., et al.Tolerance mechanisms in allergen immunotherapy. Curr Opin Allergy
Clin Immunol 20 , 591-601 (2020).
8. Belliveau, P.P. Omalizumab: a
monoclonal anti-IgE antibody. MedGenMed 7 , 27 (2005).
9. Flicker, S., Linhart, B., Wild, C.,
Wiedermann, U. & Valenta, R. Passive immunization with
allergen-specific IgG antibodies for treatment and prevention of
allergy. Immunobiology 218 , 884-891 (2013).
10. Wachholz, P.A. & Durham, S.R.
Mechanisms of immunotherapy: IgG revisited. Current opinion in
allergy and clinical immunology 4 , 313-318 (2004).
11. LaHood, N.A., et al.Immunotherapy-induced neutralizing antibodies disrupt allergen binding
and sustain allergen tolerance in peanut allergy. J Clin Invest133 (2023).
12. Orengo, J.M., et al.Treating cat allergy with monoclonal IgG antibodies that bind allergen
and prevent IgE engagement. Nat Commun 9 , 1421 (2018).
13. Storni, F., et al.Vaccine against peanut allergy based on engineered virus-like particles
displaying single major peanut allergens. J Allergy Clin Immunol145, 1240-1253 e1243 (2020).